Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer;Ocena pozytonowej tomografii emisyjnej z użyciem F-18- fluorodeoksyglukozy w rozpoznawaniu wznowy raka jelita grubego

Polski Merkuriusz Lekarski

Volumn 17, Issue SUPPL. 1, 2004, Pages 63-66

  Kula, Zbigniew ^a   Szefer, Jarosław ^a   Zuchora, Zdzisław ^a   Romanowicz, Grzegorz ^a   Pietrzak, Tomasz ^a  

^a Regional Oncology Centre Bydgoszcz   (Poland)

Author keywords

Colorectal cancer; Positron emission tomography (PET); Recurrence

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ABDOMINAL RADIOGRAPHY; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; COLORECTAL CANCER; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; ECHOGRAPHY; EVALUATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; X RAY ANALYSIS;

ADULT; CARCINOMA; COLON; COLORECTAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECTUM; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 4544294535     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Abdel-Nabi H. i wsp.: Staging of primary colorectal carcinomas with fluorine 18-fluorodeoxyglucose whole-body PET: correlation with histzpathologic and CT findings. Radiology, 1998, 206, 755-760.
2. Berger K.L. i wsp.: FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. Am. J. Roentgenol., 2000, 174, 1005-1008.
3. Bielicki D.: Rola antygenu rakowo-płodowego (CEA) w monitorowaniu terapii raka jelita grubego. Gastroenetrol. Pol., 2003, 10, 2, 173-173.
4. Delbeke D i wsp.: Staging recurrent metastatic colorectal carcinoma with PET. J. Nucl. Med., 1997, 38, 1196-1201.
5. Desch Ch.E. i wsp.: Recommended colorectal cancer surveillances guidelines by American Society of Clinical Oncology. J. Clin. Oncology, 1999, 17, 1312-1321.
6. Dimitrakopoulou-Strauss A. i wsp.: Prediction of therapy outcome with FDG PET in metastatic colorectal cancer. J. Nucl. Med., 2003, 5 (suppl.), 25P.
7. Drenth J.P.H., Nagengast P.M., Oyen W.J.G.: Evaluation of (pre) malignant colonie abnormalities: endoscopic validation of FDG-PET findings. Eur. J. Nucl. Med., 2001, 28, 1766-1769.
8. Flanagan F.L., Dendashti R, Ogunbiyi O.A. i wsp.: Utility of FDG-PFT for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann. Surg., 1998, 227, 319-323.
9. Goldberg R. i wsp.: Surgery for recurrent colon cancer: strategies for identifying respectable recurrences and success rates after resection. Ann. Intern. Med., 1998, 129, 27-35.
10. Huebner R.H. i wsp.: A meta-analysis of the literature for whole-body FDG-PET detection of recurrent colorectal cancer. J. Nucl. Med.. 2000, 41, 1177-1189.
11. Kinkel K. i wsp.: Detection of hepatic metastases from cancer of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology, 2002, 224, 748-756.
12. Królicki L., Zuchora Z.: Badania pozytonowej tomografii emisyjnej w gastrologii. VIII Warszawskie Spotkania Gastroenterologiczne, Warszawa, 14-15 czerwca 2003, 60-65.
13. Lonneux M. i wsp.: FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur. J. Nucl. Med., 2002, 23, 915-921.
14. Meta I., Seltzer M., Schiepers C. i wsp.: Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J. Nucl. Med., 2001, 42, 586-590.
15. Nakamoto Y. i wsp.: Factors related to positive PET findings in patients with high CEA levels. J. Nucl. Med., 2002, 5 (suppl.), 26-27.
16. Nowakowska D., Nowacki M.P.: Rak jelita grubego. Gastroenterologia, 2002, 3, 3, 40-47.
17. Staib L. i wsp.: Is F-18-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision-making? Am. Surg., 2000, 180, 1-5.
18. Valk P.E. i wsp.: Whole-body PET imaging with F-18-fluoroglucose in management of recurrent colorectal cancer. Arch. Surg., 1999, 134, 503-511.
19. Valk P.E. i wsp.: Cost-effectiveness of PET imaging in clinical oncology. Nucl. Med. Biol., 1996, 23, 737-743.